5.4 Infectious, Allergic & Inflammatory Peristomal Pathologies (Candidiasis, Pyoderma Gangrenosum)

Infectious, Allergic & Inflammatory Peristomal Pathologies (Candidiasis, Pyoderma Gangrenosum)

Quick Summary: Complex peristomal pathologies require precise differential diagnosis to prevent catastrophic management errors. Peristomal Candidiasis (Candida albicans) presents as bright red confluent erythema with discrete satellite pustules and intense itching, treated with topical antifungal powder crusted under a non-alcohol barrier seal (never creams or ointments). Allergic Contact Dermatitis (ACD) is a Type IV delayed hypersensitivity matching the exact geometric footprint of the offending component. Peristomal Pyoderma Gangrenosum (PPG) is an excruciatingly painful, ulcerative neutrophilic dermatosis strongly associated with Inflammatory Bowel Disease (IBD). PPG exhibits pathergy (worsening with trauma); therefore, sharp surgical debridement is strictly contraindicated, and management centers on systemic immunosuppression (biologics, steroids) and topical tacrolimus.

Misdiagnosing an inflammatory dermatosis as an infection or mechanical injury can lead to inappropriate interventions—such as sharp surgical debridement of Pyoderma Gangrenosum—with devastating clinical consequences.

---

Peristomal Candidiasis (Candida albicans)

Peristomal candidiasis is the most frequent infectious complication encountered in ostomy practice, accounting for nearly 50% of secondary microbial peristomal disorders.

                      CANDIDIASIS CLINICAL PATHWAY
  ┌────────────────────────────────────────────────────────────────────────┐
  │ RISK FACTORS: Warmth, Moisture, Occlusion, Antibiotics, Diabetes       │
  ├────────────────────────────────────────────────────────────────────────┤
  │ CLINICAL PRESENTATION:                                                 │
  │ • Vivid, "fire-engine" confluent erythema                              │
  │ • Pathognomonic **Satellite Papules & Pustules** at outer margins      │
  │ • Intense **Pruritus (Itching)** and burning sensation                 │
  ├────────────────────────────────────────────────────────────────────────┤
  │ EVIDENCE-BASED INTERVENTION:                                           │
  │ • Topical Antifungal Powder (Nystatin, Miconazole, Clotrimazole)       │
  │ • Seal with Non-Alcohol Barrier Film (WOCN Crusting Technique)         │
  │ • [STRICT CONTRAINDICATION]: Antifungal Creams / Ointments under wafer │
  │ • Refractory cases: Oral Fluconazole 100–200 mg PO daily x 7–14 days   │
  └────────────────────────────────────────────────────────────────────────┘

Pathophysiology & Risk Factors

Candida albicans is a normal commensal organism of the gastrointestinal and cutaneous microbiome. It transforms into an opportunistic pathogen under specific triggers:

• Occlusive Microenvironment: Hydrocolloid and tape barriers trap heat, perspiration, and moisture, elevating local humidity to 100% and raising skin pH.
• Systemic Antibiotic Therapy: Broad-spectrum antibiotics eliminate competing cutaneous bacteria (Staphylococcus epidermidis), permitting unchecked fungal proliferation.
• Immunosuppression & Diabetes: Systemic corticosteroids, biologics, chemotherapy, and hyperglycemia (elevated skin glucose levels) impair neutrophil phagocytosis.

Clinical Presentation & Diagnostic Differentiation

• Visual Hallmarks: Vivid, bright-red, confluent erythematous plaque beneath the barrier with pathognomonic discrete satellite macules, papules, and pinpoint pustules extending beyond the main margin into healthy skin.
• Symptomatology: Intense, unrelenting pruritus (itching) and stinging discomfort that worsens when sweating or after barrier application.
• Differential: Differentiated from Chemical ICD (which lacks satellite lesions and presents with burning rather than itching) and Folliculitis (which is restricted to hair follicles and lacks confluent bright-red plaques).

Evidence-Based Treatment Protocol

1. Topical Antifungal Powders (The Gold Standard):
   • Nystatin powder (100,000 units/g), Miconazole 2% powder, or Clotrimazole 1% powder.
   • Apply using the WOCN Crusting Technique: dust powder lightly over the entire erythematous and pustular area; gently brush off all excess unbound powder; seal with a non-alcohol liquid barrier film or spray; allow to dry completely (5–10 seconds) before applying the wafer.
2. The Absolute Contraindication to Creams & Ointments:
   • Antifungal creams (e.g., ketoconazole cream, clotrimazole cream) and ointments contain emulsifiers, mineral oil, and petrolatum that permanently destroy hydrocolloid and acrylic adhesives. Applying cream results in instantaneous pouch failure, severe leakage, and worsening chemical denudation.
3. Refractory or Extensive Disease:
   • If the infection fails to resolve after 10 to 14 days of topical powder crusting, initiate systemic oral antifungal therapy: Oral Fluconazole (Diflucan) 100 to 200 mg orally daily for 7 to 14 days.

---

Peristomal Allergic Contact Dermatitis (ACD)

Allergic Contact Dermatitis (ACD) represents an immunological reaction to a specific chemical constituent of the ostomy containment system.

Immunological Mechanism: Type IV Delayed Hypersensitivity

ACD is a cell-mediated Type IV hypersensitivity reaction occurring in two distinct phases:

1. Sensitization Phase: Initial exposure to a low-molecular-weight chemical hapten (e.g., acrylate monomer, rosin tackifier). Epidermal Langerhans cells capture the hapten, migrate to regional lymph nodes, and present it to naive T-lymphocytes, generating a sensitized memory T-cell pool over 10 to 14 days.
2. Elicitation Phase: Upon subsequent re-exposure, sensitized memory T-cells infiltrate the dermis and epidermis, releasing pro-inflammatory cytokines (IFN-$\gamma$, TNF-$\alpha$, IL-17) that induce localized spongiosis, epidermal edema, and vesicle formation within 24 to 72 hours.

Common Peristomal Allergens

• Adhesive Polymers & Tackifiers: Polyisobutylene (PIB), acrylate adhesives, rosin/colophony derivatives, ester gums.
• Tape Collar Components: Zinc oxide additives, rubber accelerators (thiurams, carbamates) used in ostomy support belts.
• Formulation Additives: Fragrances in pouch deodorants, chemical preservatives in moist cleansing wipes (methylisothiazolinone, parabens), or solvents in alcohol-based skin prep wipes.

    [ALLERGIC CONTACT DERMATITIS]              [CHEMICAL IRRITANT DERMATITIS]
    ┌─────────────────────────────┐            ┌─────────────────────────────┐
    │   Tape Collar Footprint     │            │                             │
    │   ┌─────────────────────┐   │            │        ┌─────────────┐      │
    │   │░░░░░░░░░░░░░░░░░░░░░│   │            │        │   STOMA     │      │
    │   │░░░  ┌─────────┐  ░░░│   │            │        └──────┬──────┘      │
    │   │░░░  │  STOMA  │  ░░░│   │            │          ░░░░░│░░░░         │
    │   │░░░  └─────────┘  ░░░│   │            │         ░░░░░░▼░░░░         │
    │   │░░░░░░░░░░░░░░░░░░░░░│   │            │     (Dependent Leak Channel)│
    │   └─────────────────────┘   │            │                             │
    │ (Exact Geometric Footprint) │            │ (Matches Leak / Opening Gap)│
    └─────────────────────────────┘            └─────────────────────────────┘

Clinical Presentation & Management

• Morphological Hallmark: Erythema, intense edema, weeping microvesicles, and pruritus conforming EXACTLY to the geometric footprint (sharp square, circle, or tape border) of the offending product.
• Management Steps:
  1. Eliminate the Culprit Product: Switch to an all-hydrocolloid tape-free wafer, change barrier manufacturer/brand, or eliminate pouch deodorizers and specialty wipes.
  2. Topical Corticosteroid Therapy: Apply a mid-to-high potency topical corticosteroid spray (Triamcinolone acetonide 0.147 mg/g spray) or lotion via crusting; allow to dry completely, seal with non-alcohol barrier film, and apply the hypoallergenic barrier.
  3. Diagnostic Confirmation: Refer to dermatology for formal patch testing (T.R.U.E. Test) if the allergen remains unidentified.

---

Peristomal Pyoderma Gangrenosum (PPG)

Peristomal Pyoderma Gangrenosum (PPG) is an uncommon but devastating, non-infectious, destructive autoinflammatory neutrophilic dermatosis.

Pathophysiology & Systemic Associations

• IBD Connection: Over 70% to 80% of PPG cases occur in patients with Inflammatory Bowel Disease (more prevalent in Crohn's disease than Ulcerative Colitis), though it can develop when luminal bowel disease is quiescent.
• Neutrophilic Infiltration: Driven by dysregulated innate immunity, hyperactivation of IL-1$\beta$, IL-8, and TNF-$\alpha$, leading to massive, unprovoked dermal infiltration of mature neutrophils that release matrix metalloproteinases (MMPs), causing rapid tissue liquefaction and necrosis.
• The Pathergy Phenomenon: PPG characteristically exhibits pathergy—the rapid development or explosive enlargement of a necrotic ulceration in response to minor physical trauma (such as adhesive peeling, biopsy, stitch removal, or sharp surgical debridement).

                    PPG CLINICAL CHARACTERISTICS & PATHERGY
  ┌────────────────────────────────────────────────────────────────────────┐
  │ 1. EXTREME PAIN: Severe, throbbing, out-of-proportion to ulcer size    │
  ├────────────────────────────────────────────────────────────────────────┤
  │ 2. PATHOGNOMONIC ULCER MORPHOLOGY:                                     │
  │    • Dark **violaceous (bluish-purple), ragged, undermined borders**   │
  │    • Purulent, necrotic, or fibrinous wound base                       │
  │    • Satellite pustules that coalesce into expanding ulcers            │
  ├────────────────────────────────────────────────────────────────────────┤
  │ 3. PATHERGY PHENOMENON:                                                │
  │    • Minor trauma triggers explosive tissue destruction                │
  │    • [ABSOLUTE CONTRAINDICATION]: NEVER perform sharp debridement      │
  ├────────────────────────────────────────────────────────────────────────┤
  │ 4. SYSTEMIC ASSOCIATIONS: Active/quiescent Crohn's or Ulcerative Colitis│
  └────────────────────────────────────────────────────────────────────────┘

Differential Diagnosis: PPG vs. Mimickers

---

Medical & Local Management Protocol for PPG

Successful management requires combining systemic immunomodulation with atraumatic local wound care and specialized pouching adaptations.

+---------------------------------------------------------------------------------------------------+
|                             COMPREHENSIVE PPG CLINICAL MANAGEMENT PROTOCOL                        |
+---------------------------------------------------------------------------------------------------+
| Modality               | Specific Clinical Intervention            | Actionable Nursing Rationale |
+------------------------+-------------------------------------------+------------------------------+
| Surgical Safety        | **ABSOLUTE CONTRAINDICATION TO SURGICAL   | Sharp debridement triggers   |
| Rule                   | OR SHARP DEBRIDEMENT.**                   | severe pathergy, rapidly     |
|                        |                                           | expanding the ulcer cavity.  |
+------------------------+-------------------------------------------+------------------------------+
| Systemic Therapy       | Systemic Corticosteroids:                 | Halts systemic neutrophil    |
| (Gastroenterology /    | • Prednisone 0.5–1.0 mg/kg/day PO.        | infiltration and suppresses  |
| Dermatology)           | Targeted Biologic Therapy:                | mucosal/cutaneous            |
|                        | • Infliximab (Remicade) / Adalimumab      | inflammatory cascade.        |
|                        | • Ustekinumab / Vedolizumab / Cyclosporine|                              |
+------------------------+-------------------------------------------+------------------------------+
| Topical Immunotherapy  | **Topical Tacrolimus 0.1%** (ointment or  | Potent calcineurin inhibitor;|
|                        | aqueous solution compounded in saline):   | suppresses local T-cells     |
|                        | • Apply sparingly to ulcer base.          | without causing steroid skin |
|                        | Topical Corticosteroid:                   | atrophy; promotes rapid      |
|                        | • Clobetasol 0.05% solution / powder.     | ulcer re-epithelialization.  |
+------------------------+-------------------------------------------+------------------------------+
| Local Wound Packing    | • Non-adherent contact layer (mepitel) or | Absorbs heavy exudate; fills |
| & Absorbent Fillers    |   calcium alginate / hydrofiber ribbon    | ulcer dead space; levels the |
|                        |   moistened with tacrolimus/saline.       | peristomal plane for wafer.  |
|                        | • Thin hydrocolloid wafer over packing.   |                              |
+------------------------+-------------------------------------------+------------------------------+
| Pouching System        | • **Flexible flat or soft convex barrier**| Rigid convex inserts and     |
| Modifications          | • Size opening to bridge across ulcer     | tight belts exert focal      |
|                        | • Eliminate rigid convexity and tight belt| pressure that induces        |
|                        | • Gentle, low-frequency changes (q3–4d)   | pathergy on violaceous edges.|
+------------------------+-------------------------------------------+------------------------------+

Caution: COCN Board Alert: If a practice exam question asks for the initial nursing action when encountering a painful, violaceous, undermined peristomal ulcer in a Crohn's patient, never select sharp debridement, surgical unroofing, or aggressive mechanical scrubbing. The correct action is atraumatic wound protection, local topical tacrolimus/steroids, pouch modification, and urgent gastroenterology/dermatology consultation for systemic immunosuppression.